NCT03301155

Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI

International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,036 (actual)
• Sponsor: Materia Medica Holding · Industry
• Sex: All
• Age: 1 Month – 6 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.

Detailed description

Design: an international, multicenter, double-blind, placebo-controlled, randomized study in parallel groups. The study will enroll children of either gender aged of 1 month to 6 years old. Children can participate in the study, regardless of the frequency of previous ARVI. A potential study participant should not be in the incubation (if known), prodromal, acute/subacute periods of any infectious disease (except for the recovery period). Schedule for enrollment of participants: during the period of a seasonal rise in influenza/ARVI incidence in the Russian Federation and the Republic of Uzbekistan. Screening and randomization of participants will be subject to availability of official information on the incidence of influenza/ARVI in the relevant study region. The doctor makes the first visit to the participant in the medical center or at home. After the parent/adoptive parent signs the information sheet (informed consent form), the doctor evaluates the possibility of the participant being included in the trial. If the child meets all the inclusion criteria and does not have all non-inclusion criteria, then he/she is included in the study, the doctor fills in Clinical Research Form. At visit 1 (Day 1), the participant is randomized into one of two groups: the 1st group participants will take Anaferon for children according to the preventive regimen for 12 weeks; the 2nd group participants will take Placebo according to the regimen of Anaferon for 12 weeks. In total, the study participant will be observed for 12 weeks (screening and randomization up to 1 day, preventive treatment for 12 weeks). During the observation period at 4 (Visit 2), 8 (Visit 3) and 12 (Visit 4) weeks, three visits are planned. Visits 2 (Week 4 ± 3 days) and 3 (Week 8 ± 3 days) are conducted in the form of a telephone survey of parents/adoptive parents about the participant's health status, presence/absence of symptoms of influenza/ARVI, possible use of antibacterial drugs and/or hospitalization during the course preventive therapy. Visit 4 (Week 12 ± 3 days) is carried out at home or in a medical center; the doctor collects complaints, examines the participant, registers concomitant therapy, assesses the compliance of the therapy. If in the period from 2 to 12 weeks a participant falls ill with influenza/ARVI, then he/she prematurely completes participation in the study (as having reached the primary endpoint). A participant is considered fallen ill with influenza/ARVI if the doctor identifies the following symptoms: febrile/subfebrile body temperature, presence at least one flu-like nonspecific symptom (decreased activity/impaired behavior/weakness; headache; chills) and at least one respiratory symptom (runny nose; nasal stuffiness; hoarseness/husky voice; sore throat; cough). In this case, the doctor makes an unscheduled visit (at home or in a medical center), which is final. During the visit, the doctor carries out the procedures of Visit 4. A nasopharyngeal swab is taken to identify the most common pathogens of influenza/ARVI. If ARVI/influenza occurs within the first seven days from the onset of preventive therapy, the disease will not be recorded as an adverse event and will not be taken into account to evaluate the efficacy of the study drug, since an early manifestation of influenza/ARVI may indicate that the participant was included in the study when he/she was in the incubation period of an infectious disease. During the study, concomitant therapy for underlying chronic conditions, as well as routine vaccination of the participant, are allowed, with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".

Conditions

• Preventive Medicine

Interventions

Type	Name	Description
DRUG	Anaferon for children	Tablet for oral use.
DRUG	Placebo	Tablet for oral use.

Timeline

• Start date: 2017-10-03
• Primary completion: 2019-05-20
• Completion: 2019-05-20
• First posted: 2017-10-04
• Last updated: 2020-05-06
• Results posted: 2020-05-06

Locations

33 sites across 2 countries: Russia, Uzbekistan